Literature DB >> 14691350

Renal cyclooxygenase-2 (COX-2). Physiological, pathophysiological, and clinical implications.

Bernhard K Krämer1, Martin C Kammerl, Martin Kömhoff.   

Abstract

BACKGROUND/AIMS: The role of COX-2 for renal function during renal development, for physiology and pathophysiology of renal diseases and the side effects of available COX-2 inhibitors, has gained increasing interest. We aimed therefore to review the respective role of renal COX-2.
METHODS: Review of relevant recent publications in the field, and in addition of in part unpublished data obtained in our laboratories.
RESULTS: COX-2 is 'constitutively' localized in the kidney i.e. in macula densa, TALH, interstitial cells, and is of utmost importance for normal renal development. Renal COX-2 is regulated by for example sodium and volume intake, angiotensin II, glucocorticoids often involving specific COX-2 promotor response elements. COX-2 derived prostanoids are required for preservation of renal blood flow and glomerular filtration especially in states of fluid deficit, they promote natriuresis, and furthermore may stimulate renin secretion during low-sodium intake/loop diuretic use. Conversely, COX-2 inhibitors decrease glomerular filtration, and renal perfusion, sometimes even causing acute renal failure. In addition, COX-2 inhibitors cause sodium retention, edema formation, cardiac failure and hypertension. The role of COX-2 derived prostanoids in renal inflammation or failure including diabetic nephropathy and renal transplantation remains at present controversial.
CONCLUSION: COX-2 is one of the major players in renal physiology and pathophysiology. One focus of future work should be placed on COX-2 in primary renal diseases. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14691350     DOI: 10.1159/000075811

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  7 in total

1.  Amelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice.

Authors:  Nosratola D Vaziri; Hyun Ju Kim; Hamid Moradi; Farbod Farmand; Kaveh Navab; Mohamad Navab; Susan Hama; Alan M Fogelman; Yasmir Quiroz; Bernardo Rodriguez-Iturbe
Journal:  Nephrol Dial Transplant       Date:  2010-05-20       Impact factor: 5.992

2.  Everolimus treatment downregulates renocortical cyclooxygenase-2 expression in the rat kidney.

Authors:  Klaus Höcherl; Corina Hensel; Bettina Ulbricht; Bernhard K Krämer
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

Review 3.  Redox control of renal function and hypertension.

Authors:  Ravi Nistala; Adam Whaley-Connell; James R Sowers
Journal:  Antioxid Redox Signal       Date:  2008-12       Impact factor: 8.401

4.  Effect of exercise on cardiac tissue oxidative and inflammatory mediators in chronic kidney disease.

Authors:  Y Bai; W Sigala; G R Adams; N D Vaziri
Journal:  Am J Nephrol       Date:  2008-09-17       Impact factor: 3.754

Review 5.  [Medication-induced impairment of renal function: what is important?].

Authors:  B K Krämer; M Banas; B Banas
Journal:  Internist (Berl)       Date:  2007-12       Impact factor: 0.743

6.  Renal function during rofecoxib therapy in patients with metastatic cancer: retrospective analysis of a prospective phase II trial.

Authors:  Stephan W Reinhold; Albrecht Reichle; Sonja Leiminger; Tobias Bergler; Ute Hoffmann; Bernd Krüger; Bernhard Banas; Bernhard K Krämer
Journal:  BMC Res Notes       Date:  2011-01-05

7.  Prostacyclin synthase: upregulation during renal development and in glomerular disease as well as its constitutive expression in cultured human mesangial cells.

Authors:  Thomas Klein; Günther Klaus; Martin Kömhoff
Journal:  Mediators Inflamm       Date:  2015-01-18       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.